NO920040L - Syrelabile linkermolekyler - Google Patents

Syrelabile linkermolekyler

Info

Publication number
NO920040L
NO920040L NO92920040A NO920040A NO920040L NO 920040 L NO920040 L NO 920040L NO 92920040 A NO92920040 A NO 92920040A NO 920040 A NO920040 A NO 920040A NO 920040 L NO920040 L NO 920040L
Authority
NO
Norway
Prior art keywords
aralkyl
aryl
lower alkyl
alkylene
alkyl
Prior art date
Application number
NO92920040A
Other languages
English (en)
Other versions
NO920040D0 (no
NO180417B (no
NO180417C (no
Inventor
Petrus Johannes Boon
Franciscus Michael Kaspersen
Ebo Sybren Bos
Original Assignee
Akzo Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Akzo Nv filed Critical Akzo Nv
Publication of NO920040D0 publication Critical patent/NO920040D0/no
Publication of NO920040L publication Critical patent/NO920040L/no
Publication of NO180417B publication Critical patent/NO180417B/no
Publication of NO180417C publication Critical patent/NO180417C/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/56—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/60—Two oxygen atoms, e.g. succinic anhydride
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/20—Carbocyclic rings
    • C07H15/24—Condensed ring systems having three or more rings
    • C07H15/252—Naphthacene radicals, e.g. daunomycins, adriamycins

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Ultra Sonic Daignosis Equipment (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Mushroom Cultivation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Pyrrole Compounds (AREA)
NO920040A 1990-12-31 1992-01-02 Syrelabile linkermolekyler NO180417C (no)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP90203526 1990-12-31

Publications (4)

Publication Number Publication Date
NO920040D0 NO920040D0 (no) 1992-01-02
NO920040L true NO920040L (no) 1992-07-01
NO180417B NO180417B (no) 1997-01-06
NO180417C NO180417C (no) 1997-04-16

Family

ID=8205218

Family Applications (1)

Application Number Title Priority Date Filing Date
NO920040A NO180417C (no) 1990-12-31 1992-01-02 Syrelabile linkermolekyler

Country Status (17)

Country Link
US (1) US5306809A (no)
EP (1) EP0495265B1 (no)
JP (1) JPH04334377A (no)
KR (1) KR920012063A (no)
AT (1) ATE109476T1 (no)
AU (1) AU646121B2 (no)
CA (1) CA2058595A1 (no)
DE (1) DE69103255T2 (no)
DK (1) DK0495265T3 (no)
ES (1) ES2061166T3 (no)
FI (1) FI101678B (no)
HU (1) HUT60484A (no)
IE (1) IE65406B1 (no)
NO (1) NO180417C (no)
NZ (1) NZ241217A (no)
PT (1) PT99954B (no)
ZA (1) ZA9110203B (no)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5505931A (en) * 1993-03-04 1996-04-09 The Dow Chemical Company Acid cleavable compounds, their preparation and use as bifunctional acid-labile crosslinking agents
EP0638583A1 (en) * 1993-08-13 1995-02-15 Hoechst Aktiengesellschaft Aminosugar active substances, a process for their preparation and use as pharmaceuticals
DE4433890C2 (de) * 1994-09-22 1999-02-18 Deutsches Krebsforsch Konjugat aus einem Wirkstoff und einem nicht als körperfremd angesehenen, nativen Protein
EP0871490B1 (en) * 1995-12-22 2003-03-19 Bristol-Myers Squibb Company Branched hydrazone linkers
DE19636889A1 (de) * 1996-09-11 1998-03-12 Felix Dr Kratz Antineoplastisch wirkende Transferrin- und Albuminkonjugate zytostatischer Verbindungen aus der Gruppe der Anthrazykline, Alkylantien, Antimetabolite und Cisplatin-Analoga und diese enthaltende Arzneimittel
US6030997A (en) * 1998-01-21 2000-02-29 Eilat; Eran Acid labile prodrugs
US6800616B2 (en) 1998-02-26 2004-10-05 Supergen, Inc. Treatment of HIV infections
CA2248592A1 (en) * 1998-08-31 2000-02-29 Christopher D. Batich Microspheres for use in the treatment of cancer
US6140015A (en) * 1998-12-10 2000-10-31 International Business Machines Corporation Photoresist compositions with pendant polar-functionalized aromatic groups and acid-labile branching
TWI242000B (en) 1998-12-10 2005-10-21 Univ Southern California Reversible aqueous pH sensitive lipidizing reagents, compositions and methods of use
DE69932187T2 (de) * 1999-03-11 2007-05-24 Ardenia Investments Ltd. Verbindungen für krebs-therapie
US6706892B1 (en) * 1999-09-07 2004-03-16 Conjuchem, Inc. Pulmonary delivery for bioconjugation
BRPI0003386B8 (pt) * 2000-08-08 2021-05-25 Cristalia Produtos Quim Farmaceuticos Ltda pró-droga homo ou heterodiméricas úteis no tratamento de doenças ou disfunções mediadas por fosfodiesterases; composições farmacêuticas contendo a pró-droga ou seus sais farmacêuticos aceitáveis; processo de obtenção destas pró-drogas
HUP0303719A2 (hu) * 2000-10-16 2004-03-01 Neopharm, Inc. Mitoxantron hatóanyag-tartalmú liposzómás gyógyszerkészítmények és eljárás az előállításukra
US7589180B2 (en) 2001-05-11 2009-09-15 Abbott Laboratories Inc. Specific binding proteins and uses thereof
US20100056762A1 (en) 2001-05-11 2010-03-04 Old Lloyd J Specific binding proteins and uses thereof
GB0116143D0 (en) * 2001-07-02 2001-08-22 Amersham Pharm Biotech Uk Ltd Chemical capture reagent
KR100507968B1 (ko) * 2001-08-18 2005-08-17 한국과학기술연구원 자기집합체를 형성하는 항암제-키토산 복합체 및 그의제조방법
AU2002351388A1 (en) * 2001-12-14 2003-06-30 The University Of Wyoming Methods and compositions for controlled release of drugs
US8361464B2 (en) 2002-03-01 2013-01-29 Immunomedics, Inc. Anthracycline-Antibody Conjugates for Cancer Therapy
US20060229239A9 (en) * 2002-03-08 2006-10-12 Mamoru Shoji Novel curcuminoid-factor VIIa constructs as suppressors of tumor growth and angiogenesis
US20050069551A1 (en) * 2002-03-08 2005-03-31 Emory University Cytotoxic compound-protein conjugates as suppressors of tumor growth and angiogenesis
WO2003100081A2 (en) 2002-05-24 2003-12-04 Mirus Corporation Biologically active maleamic acid derivatives with labile amide bonds
CN1733314A (zh) * 2004-08-11 2006-02-15 张阳德 半乳糖化白蛋白磁性阿霉素纳米粒的制备方法
US20060135459A1 (en) 2004-11-09 2006-06-22 Epstein Alan L Targeted innate immunity
EP1838736B1 (en) 2005-01-05 2013-03-06 Biogen Idec MA Inc. Cripto binding molecules
US8486384B2 (en) 2006-10-27 2013-07-16 University Of Southern California Lipidized interferon and methods of treating viral hepatitis
CN104013956B (zh) * 2007-01-25 2018-12-18 达娜-法勃肿瘤研究所公司 抗egfr抗体在治疗egfr突变体介导的疾病中的用途
AU2008227123B2 (en) * 2007-03-15 2014-03-27 Ludwig Institute For Cancer Research Ltd. Treatment method using EGFR antibodies and src inhibitors and related formulations
CA2696360C (en) 2007-08-14 2018-11-20 Ludwig Institute For Cancer Research Monoclonal antibody targeting the egfr receptor and uses thereof
US8618096B2 (en) * 2008-07-21 2013-12-31 The Regents Of The University Of California Prodrug compositions and methods for using the same in treating cancer and malaria
US9051354B2 (en) 2009-03-17 2015-06-09 The University Of Tokyo Protein charge regulator and protein-encapsulating polymer micelle complex
US8535948B2 (en) * 2009-03-26 2013-09-17 Institute For Systems Biology Method to determine protein interaction sites
SG176947A1 (en) 2009-07-03 2012-01-30 Avipep Pty Ltd Immuno-conjugates and methods for producing them
US20110076232A1 (en) * 2009-09-29 2011-03-31 Ludwig Institute For Cancer Research Specific binding proteins and uses thereof
AU2010336029B2 (en) 2009-12-23 2011-10-13 Avipep Pty Ltd Immuno-conjugates and methods for producing them 2
RU2013103763A (ru) 2010-07-02 2014-08-10 Ангиохем Инк. Короткие и содержащие d-аминокислоты полипептиды для терапевтических конъюгатов и их применения
WO2013012733A1 (en) 2011-07-15 2013-01-24 Biogen Idec Ma Inc. Heterodimeric fc regions, binding molecules comprising same, and methods relating thereto
WO2013023251A1 (en) 2011-08-18 2013-02-21 Affinity Biosciences Pty Ltd Soluble polypeptides
CA2860579A1 (en) 2012-01-10 2013-07-18 Biogen Idec Ma Inc. Enhancement of transport of therapeutic molecules across the blood brain barrier
GB201202268D0 (en) 2012-02-09 2012-03-28 Medical Res Council Intracellular immunity
WO2014057436A2 (en) 2012-10-10 2014-04-17 Adamed Sp. Z O.O. Anticancer conjugate
WO2014124227A1 (en) 2013-02-07 2014-08-14 Immunomedics, Inc. Pro-drug form (p2pdox) of the highly potent 2-pyrrolinodoxorubicin conjugated to antibodies for targeted therapy of cancer
WO2014141094A1 (en) 2013-03-14 2014-09-18 Adamed Sp. Z O.O. Anticancer conjugate
CA2937752C (en) 2014-02-14 2023-02-07 The Regents Of The University Of California Cyclic peroxides as prodrugs for selective delivery of agents
EP3200765A4 (en) 2014-10-03 2018-05-30 EnGeneIC Molecular Delivery Pty Ltd Enhanced loading of intact, bacterially derived vesicles with small molecule compounds
BR102016018074A2 (pt) 2015-08-07 2021-11-16 ALX Oncology Inc. Construção variante de sirp-alfa, seu método de preparação e seus usos, molécula de ácido nucleico, vetor, célula hospedeira, e composição farmacêutica
RS62151B1 (sr) 2015-08-07 2021-08-31 Alx Oncology Inc Konstrukti koji sadrže sirp-alfa domen ili njegovu varijantu
PL3380495T3 (pl) 2015-11-24 2021-12-13 Transfert Plus, S.E.C. Związki peptydowe i koniugaty peptydowe do leczenia nowotworu poprzez chemioterapię receptorową
US10800817B2 (en) 2016-12-19 2020-10-13 Morehouse School Of Medicine Compositions and methods for treating diseases by inhibiting exosome release
CN110312549B (zh) 2016-12-19 2021-06-29 莫尔豪斯医学院 用于通过抑制外泌体释放来治疗疾病的组合物和方法
CA3141130A1 (en) 2019-05-31 2020-12-03 ALX Oncology Inc. Methods of treating cancer with sirp alpha fc fusion in combination with an immune checkpoint inhibitor
BR112023022774A2 (pt) 2021-05-13 2024-01-02 Alx Oncology Inc Terapias de combinação para tratamento de câncer
US11180534B1 (en) 2021-06-04 2021-11-23 Morehouse School Of Medicine Compositions and methods for treating SARS-CoV-2 infections
AU2023208050A1 (en) * 2022-01-14 2024-07-04 Regeneron Pharmaceuticals, Inc. Verrucarin a derivatives and antibody drug conjugates thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4631190A (en) * 1981-06-26 1986-12-23 Shen Wei C Acidity-sensitive spacer molecule to control the release of pharmaceuticals from molecular carriers
US4542225A (en) * 1984-08-29 1985-09-17 Dana-Farber Cancer Institute, Inc. Acid-cleavable compound
US4744981A (en) * 1985-10-17 1988-05-17 Neorx Corporation Trichothecene antibody conjugates
US4997913A (en) * 1986-06-30 1991-03-05 Oncogen pH-sensitive immunoconjugates and methods for their use in tumor therapy
US5140013A (en) * 1989-11-28 1992-08-18 Universite Laval Maleic anhydride derivatives used as conjugation agents of anti-tumor agents on desired carriers

Also Published As

Publication number Publication date
NO920040D0 (no) 1992-01-02
EP0495265A1 (en) 1992-07-22
NO180417B (no) 1997-01-06
IE914567A1 (en) 1992-07-01
KR920012063A (ko) 1992-07-25
FI916131A (fi) 1992-07-01
AU9009891A (en) 1993-01-28
ES2061166T3 (es) 1994-12-01
AU646121B2 (en) 1994-02-10
ZA9110203B (en) 1993-01-27
NO180417C (no) 1997-04-16
DE69103255T2 (de) 1994-12-08
PT99954B (pt) 1999-06-30
US5306809A (en) 1994-04-26
IE65406B1 (en) 1995-10-18
NZ241217A (en) 1993-12-23
FI101678B1 (fi) 1998-08-14
FI101678B (fi) 1998-08-14
EP0495265B1 (en) 1994-08-03
PT99954A (pt) 1993-06-30
CA2058595A1 (en) 1992-07-01
FI916131A0 (fi) 1991-12-27
JPH04334377A (ja) 1992-11-20
ATE109476T1 (de) 1994-08-15
HUT60484A (en) 1992-09-28
DE69103255D1 (de) 1994-09-08
HU914133D0 (en) 1992-03-30
DK0495265T3 (da) 1995-01-02

Similar Documents

Publication Publication Date Title
NO920040L (no) Syrelabile linkermolekyler
MXPA03010432A (es) Inmunoconjugados del anticuerpo cd44 citotoxico.
FI912285A0 (fi) Nya bifunktionella kopplingsfoereningar, konjugat och foerfaranden foer framstaellning av dessa.
ATE294592T1 (de) Thioether enthaltende konjugate
IL64722A (en) Immunoglobulin conjugates,their preparation and pharmaceutical compositions containing them
FI900948A0 (fi) Proteiinin merkkaus
FI915780A0 (fi) Maerktae, modifierade oligonukleotider.
WO2004041307A3 (en) Compositions and methods for treating cancer using cytotoxic cd44 antibody immunoconjugates and radiotherapy
HU9500585D0 (en) Hepatotropic conjugates of antiviral drugs, carriers thereof and pharmaceutical compositions containing them